Haematologica (Dec 2022)

<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

  • Heikki Kuusanmäki,
  • Sari Kytölä,
  • Ida Vänttinen,
  • Tanja Ruokoranta,
  • Amanda Ranta,
  • Jani Huuhtanen,
  • Minna Suvela,
  • Alun Parsons,
  • Annasofia Holopainen,
  • Anu Partanen,
  • Milla E.L. Kuusisto,
  • Sirpa Koskela,
  • Riikka Räty,
  • Maija Itälä-Remes,
  • Imre Västrik,
  • Olli Dufva,
  • Sanna Siitonen,
  • Kimmo Porkka,
  • Krister Wennerberg,
  • Caroline A. Heckman,
  • Pia Ettala,
  • Marja Pyörälä,
  • Johanna Rimpiläinen,
  • Timo Siitonen,
  • Mika Kontro

DOI
https://doi.org/10.3324/haematol.2022.281692
Journal volume & issue
Vol. 108, no. 7

Abstract

Read online

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly for relapsed or refractory AML. Ex vivo drug sensitivity testing may correlate with outcomes, but its prospective predictive value remains unexplored. Here we report the results of the first stage of the prospective phase II VenEx trial evaluating the utility and predictiveness of venetoclax sensitivity testing using different cell culture conditions and cell viability assays in patients receiving venetoclax-azacitidine. Participants with de novo AML ineligible for intensive chemotherapy, relapsed or refractory AML, or secondary AML were included. The primary endpoint was the treatment response in participants showing ex vivo sensitivity and the key secondary endpoints were the correlation of sensitivity with responses and survival. Venetoclax sensitivity testing was successful in 38/39 participants. Experimental conditions significantly influenced the predictive accuracy. Blast-specific venetoclax sensitivity measured in conditioned medium most accurately correlated with treatment outcomes; 88% of sensitive participants achieved a treatment response. The median survival was significantly longer for participants who were ex vivo-sensitive to venetoclax (14.6 months for venetoclax-sensitive patients vs. 3.5 for venetoclax-insensitive patients, P<0.001). This analysis illustrates the feasibility of integrating drug-response profiling into clinical practice and demonstrates excellent predictivity. This trial is registered with ClinicalTrials.gov identifier: NCT04267081.